Shares of Moderna, Novavax and other biotech companies fell after FDA official Peter Markss resignation in protest of Robert F.…
Bloomberg journalists discuss todays biggest winners and losers in the stock market. Listen for analysis on the companies making news…
Shares of Moderna (NASDAQ: MRNA) are falling on Monday. The companys stock lost 7.9% as of 1:30 p.m. ET and…
Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what…
Its been nearly five years since Moderna (NASDAQ: MRNA) emerged as a biotech industry disruptor, with its COVID-19 vaccine playing…
Biotech is an area that may offer your portfolio growth today and earnings stability tomorrow. The idea is a biotech…
In the latest trading session, Moderna (MRNA) closed at $34.71, marking a +0.26% move from the previous day.…
Buying stocks after they have lost significant market value can lead to excellent returns in the long run, but only…
As we near the five-year anniversary of the COVID-19 pandemic, its a good time to revisit the drugmaker stock that…
The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its first…
…
After two years of double-digit gains, the S&P 500 (SNPINDEX: ^GSPC) lost its momentum -- at least temporarily -- in…
…
A big legal victory across the Atlantic Ocean was the news propelling Moderna (NASDAQ: MRNA) stock to a significant price…
Moderna anticipates 2027 release for cancer vaccine in collaboration with Merck…
Moderna hat eine Klage gegen Pfizer und Biontech gewonnen. Das Unternehmen hatte den Konkurrenten vorgeworfen, Technologien kopiert zu haben. Die…
Läuft es bei Moderna (MRNA) im Hintergrund gar nicht schlecht? Der Aktienkurs lässt mit seinem Dauerabsturz etwas anderes vermuten. Doch…
German court rules Pfizer, BioNTech infringed Moderna’s COVID-19 vaccine patent…
German court rules Pfizer, BioNTech violated Moderna’s COVID-19 vaccine patent…
A German court in Duesseldorf on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held…
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares moved higher after it was disclosed the company insiders have purchased $6 million in shares.…
…
BASEL, Switzerland and VANCOUVER, British Columbia and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a…
Viking Therapeutics (NASDAQ: VKTX) and Novavax (NASDAQ: NVAX) were two of the big winners in the biotech industry last year.…
Plus, Modernas bird flu contract with the U.S. is being evaluated…
Courtney Garcia, senior wealth advisor at Payne Capital Management, appeared on CNBCs "Power Lunch" on Thursday to give hot takes on Tesla,…
Kulmbach (www.aktiencheck.de) - Moderna-Aktienanalyse von "Der Aktionär":
Markus Bußler vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie von…
Moderna (NASDAQ: MRNA) became a hot investment during the pandemic as its COVID vaccine made investors bullish on its future.…
Moderna hat sich mit seinem mRNA-Impfstoff gegen COVID-19 einen Namen gemacht, doch das Unternehmen arbeitet längst an einer breiteren…
An den New Yorker Börsen hat sich am Freitag aufgrund von Konjunktur- und Inflationssorgen die Kursschwäche verfestigt. Der Leitindex Dow…
An den New Yorker Börsen hat sich am Freitag aufgrund von Konjunktur- und Inflationssorgen die Kursschwäche verfestigt. Der Leitindex Dow…
Moderna stock rises amid new virus concerns…
In the dark days of the coronavirus pandemic, Moderna (NASDAQ: MRNA) was a ray of light in more ways than…
Charlotte (www.aktiencheck.de) - Moderna-Aktienanalyse der Bank of America (BofA):
1. Hintergrund der Kurszielsenkung
Die BofA hat das Kursziel für die Aktie von…
Moderna has limited upside: Barclays…
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares added more than 8% during Tuesday’s session as investors remained optimistic about the company’s long-term...…
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares added more than 8% during Tuesday’s session as investors remained optimistic about the company’s long-term...…
…
London (www.aktiencheck.de) - Moderna-Aktienanalyse von Barclays:
Rating und Kursziel
Barclays hat die Aktie von Moderna Inc. (ISIN: US60770K1079, WKN: A2N9D9, Ticker-Symbol: 0QF,…
…
MRNA earnings call for the period ending December 31, 2024.…
MRNAs earnings and revenues surpass estimates in the fourth quarter of 2024. The company reiterates 2025 total revenue guidance.…
The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 vaccine sales.…
These are the stocks posting the largest moves in premarket trading.…
It marks another quarter of growing pains for the company, which is racing to launch new products and recover from…
Das Biotechnologieunternehmen Moderna hat seine Ergebnisse für das vierte Quartal 2024 veröffentlicht.…
Im abgelaufenen Jahresviertel hat Moderna klare Verluste verzeichnet und je Aktie ein Minus von 2,91 US-Dollar erwirtschaftet. Zum Vorjahreswert von…
Moderna, Palo Alto and Applied Materials fall premarket; GameStop, Airbnb rise…
Moderna Inc (NASDAQ:MRNA, ETR:0QF) stock moved higher after the pharmaceutical firm posted mixed results for the fourth quarter. It reported…
Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to scale down manufacturing…